BOSTON--(BUSINESS WIRE)--DeepCure, Inc. (“DeepCure”), a biotech company developing an automated molecular foundry powered by a quintillion member small molecule library and artificial intelligence (AI) to accelerate drug discovery, announced today the appointment of Dr. Han Lim as Chief Business Officer (CBO). Dr. Lim will lead all business development, portfolio planning, and corporate strategy functions at the company.
Dr. Lim is one of the pioneers in establishing the first-generation of AI drug discovery companies, and has more than 16 years experience leading high-performing teams in business development, strategy and research. He was previously Chief Business Officer at Atomwise, where he launched its internal drug discovery pipeline, and was instrumental in growing the company through two rounds of financing totaling $168M. He secured Atomwise’s AI drug discovery partnerships with companies such as Eli Lilly and Charles River Laboratories, and established a global program of more than 500 academic research projects. He and his team also created US and international joint-ventures, such as A2i Therapeutics, an immuno-oncology company.
“I’m thrilled to welcome Han to DeepCure, who brings a proven track record of success and leadership. He is a world-class scientist with deep experience at the convergence of biology, chemistry, and computational science. He shares our commitment to rigorous science and discovering potential therapies for patients with significant unmet medical need,” said Kfir Schreiber, CEO of DeepCure. “His passion and expertise will enable our partners to harness the full power of our technology for small molecule drug discovery.”
"DeepCure's team have focused on what drug hunters need – rapid selection and optimization of compounds via better predictions of multiple pharmacological properties, faster compound synthesis, and quick turn around of assays,” said Dr. Han Lim, Chief Business Officer, DeepCure. “The molecular foundry being built by DeepCure, to automate synthesis and assays for selected compounds from its quintillion member library, is a potential game changer - enabling AI predictions to be rapidly validated and iterated. The combination of the AI platform, foundry and experienced scientists at DeepCure is very compelling. This is the right team to harness the potential of AI for drug discovery.”
Dr. Lim spent a decade on the faculty at the University of California Berkeley, where his lab focused on systems biology and bioengineering. He has a medical degree from the University of Queensland, a PhD from the University of Cambridge, and was a postdoctoral researcher in the Department of Physics at MIT. Dr. Lim has published in top scientific journals including Nature, Nature Genetics, and PNAS, and has presented at international scientific and industry conferences.
DeepCure was founded by researchers at the Massachusetts Institute of Technology (MIT) to accelerate breakthroughs in drug discovery. The company has developed an AI platform for novel hit discovery and optimization of small molecule potency, selectivity and ADME properties. To accelerate preclinical drug discovery, DeepCure is building an automated laboratory to rapidly iterate the design, synthesis and evaluation of compounds from a quintillion member chemical library. DeepCure is currently focused on developing a pipeline of immunology and oncology assets. The Company is headquartered in Boston, MA with international offices. For more information, visit www.deepcure.ai/.